Recently there has been a stress on personalized medicine in the treatment of cancer. We know that cancer although the same type, such as epithelial ovarian cancer ( the most common ovarian cancer), may vary from patient to patient due to the cancer's unique molecular makeup. Standard treatment that may work for one woman may not work for another and the cancer will progress. What is needed is an understanding of the molecular and genetic makeup of each individual's cancer to best treat the disease.
The Cancer Institute of New Jersey has begun an initiative called Precision Medicine. This initiative which includes the use of bioinformatics will allow researchers to collect both clinical and genetic information to determine diagnosis, prognosis and best course of treatment in a more targeted manner than in the past. This is good news for cancer patients.
What makes me especially happy is that this initiative will be lead by Lorna Rodriguez, MD, PhD chief of gynecologic oncology at CINJ since 2000, one of my gyn-oncs and lead investigator of the selenium clinical trial I participated in. It is because of her many investigator-initiated trials into cancer metastasis and drug resistance that makes her the perfect person to lead this research.
To read further about this program please click here.
Every Day is a Blessing! I am especially blessed to be treated at a center that is at the forefront of cancer research.